Dr Reddys Laboratories Ltd

A price-to-earnings ratio of 29.79 against an industry average of 37.19 reveals a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return trails the Sensex by 2.26 percentage points, the three-month performance shows a sharper divergence with a decline of 12.08% versus the Sensex’s 2.31% gain. The data paints a complex picture of valuation and momentum across timeframes.

Dr Reddys Laboratories Ltd, a prominent mid-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a downgrade from a Hold to a Sell rating, reflecting growing concerns over its relative underperformance and valuation metrics. Despite a modest uptick in share price, the company’s longer-term returns lag behind the broader Sensex benchmark, underscoring the challenges it faces within the competitive pharmaceutical landscape and the critical implications of its Nifty 50 index membership.

Dr Reddys Laboratories Ltd, a prominent constituent of the Nifty 50 index, has recently been downgraded from a Hold to a Sell rating, reflecting growing concerns over its subdued market performance and valuation pressures within the Pharmaceuticals & Biotechnology sector. This development underscores the stock’s evolving role within the benchmark index and highlights shifting institutional sentiments.

A price-to-earnings ratio of 29.42 against an industry average of 36.78 reveals a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return lags the Sensex by nearly 8 percentage points, the three-month performance shows a sharper decline, signalling a complex momentum picture.

A price-to-earnings ratio of 29.81 against an industry average of 36.83 reveals a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return trails the Sensex by a significant margin, the recent three-month performance shows even sharper underperformance, painting a complex picture of momentum and valuation tension.

Dr Reddys Laboratories Ltd, a prominent mid-cap pharmaceutical player and a constituent of the Nifty 50 index, continues to face headwinds despite its benchmark status. Recent data reveals a modest intraday gain of 0.07%, yet the stock remains under pressure relative to its moving averages and sector peers, reflecting broader challenges in the Pharmaceuticals & Biotechnology sector.

Dr Reddys Laboratories Ltd experienced a challenging week from 20 to 24 July 2026, with its stock price declining by 4.81% to close at Rs.1,152.60, significantly underperforming the Sensex which fell 1.85% over the same period. The week was marked by a series of negative developments including a sharp gap down, a new 52-week low, and a downgrade in technical momentum, all contributing to sustained selling pressure and heightened volatility.

Dr Reddy's Laboratories Ltd reported mixed Q1 FY27 results, with net sales up 7.33% sequentially but down 5.51% year-on-year, and a net profit recovery of 101.13% from the previous quarter, though still down 68.67% year-on-year. The company faces significant challenges with operating margins collapsing to 10.65% and a heavy reliance on non-operating income, indicating ongoing profitability issues.

A price-to-earnings ratio of 23.53 against an industry average of 35.70 reveals a significant valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return trails the Sensex marginally, the recent three-month performance shows a pronounced underperformance, signalling a shift in momentum that warrants closer examination.

A price-to-earnings ratio of 24.00 against an industry average of 36.12 marks a significant valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return of -3.98% slightly outperforms the Sensex’s -6.20%, shorter-term performance reveals sharper declines, painting a complex picture of momentum and valuation tension.

A price-to-earnings ratio of 24.36 against the Pharmaceuticals & Biotechnology industry average of 36.04 reveals a significant valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMOJO, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return of -3.45% slightly outperforms the Sensex’s -5.44%, shorter-term performance shows a more nuanced picture, with recent months reflecting underperformance. The data presents a complex valuation-performance tension for this large-cap pharmaceutical player.

Dr Reddys Laboratories Ltd, a prominent large-cap pharmaceutical stock and a constituent of the Nifty 50 index, has recently exhibited a nuanced performance profile marked by heightened volatility and shifting institutional holdings. Despite trading below key moving averages, the stock outperformed its sector and the broader Sensex benchmark on 20 Jul 2026, underscoring its strategic importance within India’s benchmark indices and the evolving investor sentiment surrounding it.

Dr Reddys Laboratories Ltd experienced a challenging week from 13 to 17 July 2026, with its share price declining 2.78% to close at Rs.1,210.85, underperforming the Sensex which remained flat over the same period. The week was marked by a significant downgrade to a Sell rating amid weak financial results and deteriorating technical momentum, reflecting growing investor caution in the pharmaceutical heavyweight.